Sharemaestro Newsreel

Precipio Announces Q2-2026 Financial Results

Precipio, Inc. (NASDAQ: PRPO) announced strong financial results for Q2-2026, with record quarterly revenue of $7.0 million, a 22% year-over-year increase from Q2-2025. The company also returned to positive Adjusted EBITDA of $0.4 million and significantly strengthened its cash position to over $3 million …

Tenet Healthcare (NYSE:THC) Lowered to "Buy" Rating by Wall Street Zen

Wall Street Zen downgraded Tenet Healthcare (NYSE:THC) from a "strong-buy" to a "buy" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $273. The company recently reported strong quarterly earnings of $6.12 per share, exceeding estimates, with …

Femasys 2Q Loss/Shr $1.33 >FEMY

Femasys reported a second-quarter loss per share of $1.33. This financial update indicates the company's performance for the recent quarter.

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Oramed Pharmaceuticals (NASDAQ:ORMP) from a "hold" to a "buy" rating, though MarketBeat's overall analyst rating for the company remains "Hold." Oramed Pharmaceuticals opened at $4.48, with a market capitalization of $186.35 million. The company recently reported a quarterly loss …

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts

Analysts have given Pyxis Oncology (NASDAQ:PYXS) a "Moderate Buy" rating, with eight out of ten recommending a buy, one a hold, and one a sell, and an average 12-month price target of $7.50. Recent analyst actions have been mixed, including a downgrade from Wall …

Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded Neumora Therapeutics (NASDAQ:NMRA) from a "strong sell" to a "sell" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $6.57. NMRA shares recently dropped by 7.5%, opening at $1.60, and the company reported …

Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts

Apogee Therapeutics Inc. (NASDAQ:APGE) has received a consensus "Hold" rating from analysts, with 15 out of 20 firms issuing hold ratings. The average 12-month price target is $124.43, while the stock recently opened at $134.55. The company reported a quarterly loss of $1.14 per …

Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded Nkarta (NASDAQ:NKTX) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an $11.20 target. Nkarta's shares opened at $2.33, near its 1-year low, and the company reported a quarterly loss of …

NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen

Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Wave Life Sciences Ltd. (WVE), highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, breakout, and short positions, with specific entry zones, targets, and stop …

Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen

CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded CytomX Therapeutics (NASDAQ:CTMX) stock rating from "sell" to "hold," though the overall analyst consensus remains a "Buy" with an average price target of $11.90. The company reported a quarterly loss of $0.09 per share and revenue of $1.42 million, …

Wall Street Zen Downgrades National Research (NASDAQ:NRC) to Hold

Wall Street Zen Downgrades Intuitive Surgical (NASDAQ:ISRG) to Hold

Wall Street Zen downgraded Intuitive Surgical (NASDAQ:ISRG) from "Buy" to "Hold," despite a broader "Moderate Buy" consensus among analysts with an average price target of $508.68. Intuitive Surgical recently surpassed quarterly estimates with $2.80 EPS and $2.89 billion in revenue, representing an 18.4% year-over-year …

Gilead Sciences (NASDAQ:GILD) Upgraded to "Buy" at Wall Street Zen

Wall Street Zen has upgraded Gilead Sciences (NASDAQ:GILD) from a "Hold" to a "Buy" rating. This upgrade aligns with a "Moderate Buy" consensus among analysts, with an average price target of $158.04. The company recently reported strong quarterly results, exceeding revenue expectations, despite some …

Codexis (NASDAQ:CDXS) Cut to "Sell" at Wall Street Zen

Wall Street Zen has downgraded Codexis (NASDAQ:CDXS) from "Hold" to "Sell," causing the stock to fall 2.5% to $1.56, significantly below its 12-month high. Despite beating quarterly earnings expectations with a smaller loss and higher revenue than anticipated, the biotechnology company remains unprofitable, with …

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

Tactile Systems Technology (NASDAQ:TCMD) Downgraded to "Buy" Rating by Wall Street Zen

Wall Street Zen downgraded Tactile Systems Technology (NASDAQ:TCMD) from "strong buy" to "buy," although the broader analyst consensus remains a "Moderate Buy" with an average price target of $38.40. The company recently reported strong quarterly earnings per share of $0.34, exceeding estimates, with revenue …

Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold"

Wall Street Zen has upgraded Harrow (NASDAQ:HROW) from "sell" to "hold," though overall analyst sentiment remains a "Moderate Buy" with a target of $69.43. This comes as Harrow reported a quarterly loss that missed estimates despite slightly exceeding revenue expectations. Institutional investors hold a …

Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded Sionna Therapeutics (NASDAQ:SION) to a "strong sell" rating. This comes amidst broader analyst sentiment leaning towards "hold," with the stock opening significantly below its 52-week high and reporting a quarterly loss that missed estimates. Insider selling has occurred, though some …

Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen

Wall Street Zen has upgraded Ovid Therapeutics (NASDAQ:OVID) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with a target price of $5.71. The company recently reported a quarterly loss of $0.08 per share, outperforming expectations, and …

Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Celcuity (NASDAQ:CELC) from a "sell" to a "strong sell," despite a "Moderate Buy" consensus from other analysts with an average price target of $153.64. The company's shares opened at $92, below its 52-week high, and reported a larger-than-expected quarterly loss …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen

Wall Street Zen downgraded Mineralys Therapeutics (NASDAQ:MLYS) to "Strong Sell" following a significant second-quarter earnings miss, where the company lost $2.85 per share against an expected $0.55 loss. Despite this, the broader analyst consensus remains a "Moderate Buy" with a $49.33 price target. Insider …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell

Wall Street Zen downgraded Kodiak Sciences (NASDAQ:KOD) from "hold" to "sell" on Saturday, despite the broader analyst consensus being a "Moderate Buy." The company's shares opened near their 52-week high at $41.35, but Kodiak Sciences reported a larger-than-expected quarterly loss of $1.05 per share. …

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …

Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Tenax Therapeutics (NASDAQ:TENX) from a "sell" to a "strong sell" rating. This comes amidst other analysts also reducing their ratings, though the broader consensus remains a "Moderate Buy" with a $14 average price target. The company, which is developing pain-management …

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by …

ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded ADC Therapeutics (NYSE:ADCT) from a "sell" to a "hold" rating. The company reported a quarterly loss of $0.11 per share, beating analyst estimates, with revenue of $19.25 million also exceeding expectations. Despite mixed analyst coverage, the stock has a consensus …

Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear

Outlook Therapeutics (OTLK) stock has declined significantly over the past five years, yet recent valuation checks do not indicate it is a clear bargain. The company's negative shareholder equity makes its Price-to-Book (P/B) ratio unreliable for valuation, and despite the recent approval of LYTENAVA …

Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Verastem (NASDAQ:VSTM) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $13.83. The biopharmaceutical company recently exceeded quarterly earnings expectations, reporting a loss of $0.35 per share against an estimated …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Maplight Therapeutics (NASDAQ:MPLT) from "strong sell" to "sell," though the stock still holds a consensus "Moderate Buy" rating with an average price target of $29.67. The company recently reported better-than-expected quarterly EPS of -$1.32, and an insider director purchased 15,620 …

Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8

Maxim Group has reiterated its Buy rating for Palisade Bio (PALI.US) and maintained its target price at $8. This indicates continued confidence from the firm in the company's prospects.

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded Savara (NASDAQ:SVRA) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Moderate Buy" with a $10.14 price target. The company recently reported a quarterly loss of $0.16 per share, missing expectations, and analysts have lowered …